Leonard Post Sells 1,000 Shares of CG Oncology (NASDAQ:CGON) Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 1,000 shares of CG Oncology stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $74.54, for a total transaction of $74,540.00. Following the sale, the director directly owned 1,000 shares in the company, valued at $74,540. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

CG Oncology Stock Performance

NASDAQ CGON opened at $80.68 on Thursday. The firm’s fifty day moving average price is $70.51 and its two-hundred day moving average price is $65.26. The stock has a market cap of $7.15 billion, a PE ratio of -29.99 and a beta of 0.23. CG Oncology, Inc. has a fifty-two week low of $24.85 and a fifty-two week high of $80.97.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. The firm had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.36 million. As a group, sell-side analysts predict that CG Oncology, Inc. will post -3.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CG Oncology

Large investors have recently added to or reduced their stakes in the business. Fiduciary Financial Advisors bought a new position in shares of CG Oncology during the 2nd quarter worth approximately $28,000. NFSG Corp acquired a new position in shares of CG Oncology during the 1st quarter valued at $34,000. Whittier Trust Co. of Nevada Inc. bought a new position in CG Oncology during the fourth quarter worth $27,000. Comerica Bank boosted its stake in CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after acquiring an additional 515 shares in the last quarter. Finally, Fifth Third Bancorp acquired a new stake in CG Oncology in the first quarter worth $74,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on CGON shares. Royal Bank Of Canada cut their price target on CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a research note on Friday, August 7th. Truist Financial upped their price objective on CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Wall Street Zen lowered shares of CG Oncology from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Piper Sandler lifted their target price on shares of CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a report on Friday, July 17th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $83.18.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.